Whole Blood DNA Extraction Methods Compared
|
By LabMedica International staff writers Posted on 14 Aug 2014 |
In the clinical laboratory, nucleic acids are routinely isolated from various types of specimen, including blood, sputum, cerebrospinal fluid, stool, urine, buccal swabs, and respiratory specimens, for use in a wide array of molecular diagnostic tests.
Both the quality and quantity of the extracted nucleic acids are crucial to the successful implementation of downstream molecular diagnostic procedures, including polymerase chain reaction (PCR), quantitative PCR, microarray analyses, and direct sequencing.
Laboratory scientists at the Asian Medical Center (Seoul, Republic of Korea) collected blood samples from five healthy donors and all DNA extraction processes were performed within six hours of specimen collection. The team evaluated the efficiency of three extraction methods by comparison based on the total amount of extracted DNA adjusted by input blood volume, and the purity of the extract. Polymerase chain reaction analyses were performed using the Actin Beta gene (ACTB) as a target. The real-time PCR assay was carried out for housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Total elapsed time for DNA extraction was compared.
The three extraction methods were the Nextractor NX-48 system, (Genolution; Seoul, Republic of Korea); the manual QIAamp DNA Blood Mini Kit (Qiagen; Valencia, CA, USA), and the automated Maxwell system method (Promega; Madison, WI, USA). Following DNA extraction, the optical density of each sample was read at 260 nm and 280 nm using a NanoDrop ND-2000c spectrophotometer (Thermo Scientific; Wilmington, DE, USA). Real-time PCR was run on a SmartCycler system (Cepheid; Sunnyvale, CA, USA).
Extraction efficiencies for the QIAamp was 25.4 ± 3.8 ng/μL, for the Maxwell it was 9.2 ± 0.6 ng/μL, and the Nextractor system was the most efficient at 31.0 ± 5.6 ng/μL. No significant differences in purity were observed among three methods. DNA extracted using the ACTB was successfully amplified in all three methods. There were no obvious differences in cycle threshold (Ct) values for GAPDH real-time PCR. Total elapsed time for DNA extraction was about 50 minutes for the QIAamp, 40 minutes for the Maxwell, and 20 minutes for the Nextractor.
The authors concluded that both the purity and yield of the Nextractor system were similar to that of manual extraction. The relative speed and low hands-on time represent clear benefits over manual processes. Therefore, the Nextractor system represents a useful alternative to manual DNA extraction in clinical laboratories that is suitable for many downstream molecular diagnostic applications. The study was published in the August 2014 issue of the journal Clinica Chimica Acta.
Related Links:
Asian Medical Center
Genolution
Cepheid
Both the quality and quantity of the extracted nucleic acids are crucial to the successful implementation of downstream molecular diagnostic procedures, including polymerase chain reaction (PCR), quantitative PCR, microarray analyses, and direct sequencing.
Laboratory scientists at the Asian Medical Center (Seoul, Republic of Korea) collected blood samples from five healthy donors and all DNA extraction processes were performed within six hours of specimen collection. The team evaluated the efficiency of three extraction methods by comparison based on the total amount of extracted DNA adjusted by input blood volume, and the purity of the extract. Polymerase chain reaction analyses were performed using the Actin Beta gene (ACTB) as a target. The real-time PCR assay was carried out for housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Total elapsed time for DNA extraction was compared.
The three extraction methods were the Nextractor NX-48 system, (Genolution; Seoul, Republic of Korea); the manual QIAamp DNA Blood Mini Kit (Qiagen; Valencia, CA, USA), and the automated Maxwell system method (Promega; Madison, WI, USA). Following DNA extraction, the optical density of each sample was read at 260 nm and 280 nm using a NanoDrop ND-2000c spectrophotometer (Thermo Scientific; Wilmington, DE, USA). Real-time PCR was run on a SmartCycler system (Cepheid; Sunnyvale, CA, USA).
Extraction efficiencies for the QIAamp was 25.4 ± 3.8 ng/μL, for the Maxwell it was 9.2 ± 0.6 ng/μL, and the Nextractor system was the most efficient at 31.0 ± 5.6 ng/μL. No significant differences in purity were observed among three methods. DNA extracted using the ACTB was successfully amplified in all three methods. There were no obvious differences in cycle threshold (Ct) values for GAPDH real-time PCR. Total elapsed time for DNA extraction was about 50 minutes for the QIAamp, 40 minutes for the Maxwell, and 20 minutes for the Nextractor.
The authors concluded that both the purity and yield of the Nextractor system were similar to that of manual extraction. The relative speed and low hands-on time represent clear benefits over manual processes. Therefore, the Nextractor system represents a useful alternative to manual DNA extraction in clinical laboratories that is suitable for many downstream molecular diagnostic applications. The study was published in the August 2014 issue of the journal Clinica Chimica Acta.
Related Links:
Asian Medical Center
Genolution
Cepheid
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
- Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
- Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
- New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
- Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
- Liquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis
- Newborn Screening Program Adds Spinal Muscular Atrophy Testing Across England
- Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
- Liquid Biopsy Assay Enriches Tumor DNA for Early Detection and Monitoring
- Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
- Point-of-Care Multiplex PCR Test Submitted to FDA for Flu A/B and RSV Detection
- New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance
- Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
- Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
- AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
- Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
Channels
Clinical Chemistry
view channel
Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air
Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more
Head-to-Head Study Compares Blood Tests for Early Alzheimer’s Disease Detection
Accurate, scalable diagnostics are becoming increasingly important as disease-modifying therapies reshape Alzheimer’s disease care, yet many patients still rely on invasive cerebrospinal fluid sampling... Read more
Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy
Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
Clinical decisions often rely on chronological age, yet organs can age biologically at different rates that remain hard to assess. Noninvasive detection of organ-specific aging could support disease monitoring... Read more
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more








